|
|
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.United States |
First Approval Date08 May 1984 |
Target- |
Mechanism- |
|
Originator Org.- |
|
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
杏芩感咳颗粒治疗感冒后咳嗽(风热伏肺证)的有效性和安全性随机对照剂量探索性Ⅱ期临床试验
[Translation] A randomized controlled dose-exploratory phase II clinical trial on the efficacy and safety of Xingqin Ganke granules in the treatment of cough after cold (wind-heat in the lungs syndrome)
以安慰剂为对照,初步评价杏芩感咳颗粒治疗感冒后咳嗽(风热伏肺证)的有效性和安全性,并进行剂量探索。
[Translation] Using placebo as a control, the efficacy and safety of Xingqin Ganke Granules in treating cough after cold (wind-heat in the lungs syndrome) were preliminarily evaluated, and a dose exploration was conducted.
100 Clinical Results associated with Shijiazhuang Hankang Biochemical Medicine Co., Ltd.
0 Patents (Medical) associated with Shijiazhuang Hankang Biochemical Medicine Co., Ltd.
100 Deals associated with Shijiazhuang Hankang Biochemical Medicine Co., Ltd.
100 Translational Medicine associated with Shijiazhuang Hankang Biochemical Medicine Co., Ltd.